Viking Therapeutics (VKTX) investor relations material

Key clinical program updates

• Lead compound VK2735, a dual GLP-1/GIP agonist, is in phase III for obesity with both subcutaneous and oral formulations advancing in trials.

• Oral VK2735 showed up to 12% weight loss at 13 weeks in phase II, with durable effects and promising tolerability.

• Subcutaneous VK2735 achieved nearly 15% weight loss at 13 weeks, with over 90% of efficacy retained at week 17.

• Maintenance dosing regimens are being explored, with data supporting transition from high to lower doses while maintaining efficacy.

• An amylin agonist is planned to enter clinical trials by late this year or early next year.

Safety, tolerability, and trial design insights

• Most adverse events were mild to moderate, with GI events primarily occurring early and resolving quickly.

• Slower titration rates are being used in phase III to improve tolerability, with real-world dosing expected to be individualized.

• Placebo-controlled trials remain the regulatory standard, with patient retention aided by guaranteed access to active therapy post-trial.

• BMI cutoffs for phase III trials align with industry standards, allowing inclusion of patients with comorbidities.

• No regulatory path exists for maintenance-only approval; all studies focus on weight loss as the primary endpoint.

Strategic and market positioning

• Over $800 million in cash provides runway to complete phase III trials and support aggressive development.

• Lean operational model with just over 50 employees, leveraging external vendors for execution.

• Direct-to-patient channels are seen as a major opportunity, reducing the need for large sales infrastructure.

• Open to partnerships but prepared to commercialize in-house if needed, with a focus on building thoughtfully.

• Success is defined by having multiple competitive products on the market and leveraging global direct-to-patient models.